Search Results
May 26, 2026, 11:58 ET New Med to Manage Tourette Syndrome Shows Promise in Phase III Clinical Trial
May 26, 2026, in JAMA Neurology describing the results of a recently completed phase III clinical trial of the first drug designed to help children with this condition. Next step: the drug maker Emalex Biosciences plans to seek approval from
More news about: Cincinnati Children's Hospital Medical Center
May 26, 2026, 11:18 ET Mountain Province Diamonds Announces Mailing of Meeting Materials For Annual and Special Meeting of Shareholders, Seeks Approvals to Facilitate Potential Restructuring Transaction
"Manual"); (ii) approve an ordinary resolution (the "Facility Fee Resolution") approving a US$1,000,000 facility fee (the "Facility Fee"); (iii) approve an ordinary resolution (the "Delisting Resolution") approving the voluntary delisting of the Shares (the "Delisting") from the
More news about: Mountain Province Diamonds Inc.
May 26, 2026, 10:50 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
an RNA-targeted medicine being evaluated for the treatment of severe hypertriglyceridemia. Olezarsen is designed to lower the body's production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood. Olezarsen is approved in the U.S., European Union, and other
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 10:46 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
an RNA-targeted medicine being evaluated for the treatment of severe hypertriglyceridemia. Olezarsen is designed to lower the body's production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood. Olezarsen is approved in the U.S., European Union, and other
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 10:35 ET Tungsten's 557% Run Meets a District-Scale Critical-Minerals Story in British Columbia
Mountain tungsten project in Nevada on May 6, 2026. The PFS is being supported by a US$6.2 million U.S. Department of War Defense Production Act Title III investment in Guardian Metal's wholly-owned subsidiary, Golden Metal Resources (USA) LLC[5]. Required drilling for resource
More news about: Equity Insider
May 26, 2026, 10:27 ET Bitmine Immersion Technologies (BMNR) Công Bố Lượng ETH Nắm Giữ Đạt 5,39 Triệu Token, Đưa Tổng Tài Sản Tiền Mã Hóa và Tiền Mặt Lên Mức 12,3 Tỷ USD
Bitmine hiện vẫn được hỗ trợ bởi một nhóm các nhà đầu tư tổ chức hàng đầu như Cathie Wood của ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital và nhà đầu tư cá nhân Thomas "Tom" Lee nhằm giúp Bitmine đạt mục tiêu sở hữu 5% ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
May 26, 2026, 10:12 ET Bitmine Immersion Technologies (BMNR) gibt bekannt, dass der ETH-Bestand 5,39 Millionen Token erreicht hat und sich der Gesamtbestand an Kryptowährungen und Barmitteln auf 12,3 Mrd. USD beläuft
wird weiterhin von einer Gruppe führender institutioneller Investoren unterstützt, darunter Cathie Wood von ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital und der Privatinvestor Thomas „Tom" Lee, um das Ziel von Bitmine zu unterstützen, 5 % der ETH zu erwerben
More news about: Bitmine Immersion Technologies, Inc.
May 26, 2026, 09:31 ET INVESTOR NOTICE: Stellantis N.V. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - STLA
Stellantis' confidence in the electrification market or otherwise defendants' faith in Stellantis' ability to capitalize on such growth was misplaced; and (iii) Stellantis would ultimately see earnings slide through repeated guidance reductions despite efforts to minimize the potential of any impact until it
More news about: Robbins Geller Rudman & Dowd LLP
May 26, 2026, 09:28 ET INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MEDP
book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio; (iii) Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations
More news about: Robbins Geller Rudman & Dowd LLP
May 26, 2026, 09:15 ET Lion Group Holding Ltd. Reaffirms Long-Term Commitment to Hyperliquid (HYPE) Holdings
that offers a wide spectrum of products and services, including (i) total return swap (TRS) trading, (ii) contract-for-difference (CFD) trading, and (iii) Over-the-counter (OTC) stock options trading. Additional information may be found at http://ir.liongrouphl.com.Forward-Looking
More news about: Lion Group Holding Ltd.
May 26, 2026, 09:00 ET IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action - Contact The Gross Law Firm
adverse facts concerning the efficacy and safety of its TACTI-004 Phase III clinical trial study. On March 13, 2026, Immutep issued a press release announcing that the Independent Data Monitoring (IDMC) for the TACTI-004 Phase III study recommended that the trial be discontinued following a planned interim
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 29, 2026 in Pinterest, Inc. Lawsuit - PINS
impact of U.S. tariffs on the macroeconomic environment in which the Company operated, including the foreseeable impact on its advertising partners; (iii) the impact of the foregoing on Pinterest's advertising revenues was significant enough that Pinterest was facing and/or likely to face an imminent restructuring;
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET The Gross Law Firm Reminds Upstart, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 8, 2026 - UPST
performing its risk-separation processes; (ii) accordingly, Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (iii) Model 22's overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart's revenue results,
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET RGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Limited Securities Lawsuit - Contact The Gross Law Firm
manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET GPK Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Graphic Packaging Holding Company Securities Lawsuit - Contact The Gross Law Firm
and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET The Gross Law Firm Reminds Babcock & Wilcox Enterprises, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 15, 2026 - BW
(ii) Applied Digital did not need the products and services that B&W would purportedly supply pursuant to the power generation LNTP and contract; (iii) the foregoing, at the very least, would raise questions about the parties' actual intent behind entering into the power generation LNTP and contract,
More news about: The Gross Law Firm
May 26, 2026, 09:00 ET Adela Highlights Progress on Multi-Cancer Early Detection Study at the 2026 ASCO Annual Meeting
annual cancer deaths in the United States. An additional 3,900 cancer-free control participants have been enrolled. A subset of participants with Stage I–III lung cancer will undergo additional blood draws and longitudinal follow-up, enabling training and validation of a test for MRD-based recurrence detection.Adela's
More news about: Adela
May 26, 2026, 09:00 ET Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Diagnostics; (ii) the potential future development, validation, regulatory review, commercialization, manufacture, and distribution of a BDBV test; (iii) the Company's ability to rapidly respond to emerging infectious disease threats; (iv) the potential utility, effectiveness, and adoption of the Co-Dx
More news about: Co-Diagnostics
May 26, 2026, 09:00 ET Primally Pure Urges Consumers and FDA to Rethink Sunscreen Ingredients
Administration. (2019). Sunscreen drug products for over-the-counter human use; proposed rule. Federal Register, 84(38), 6204–6275.iii Matta, M. K., Zusterzeel, R., Pilli, N. R., Patel, V., Volpe, D. A., Florian, J., Oh, L., Bashaw, E., Zineh, I., Sanabria, C., Kemp, S., Strauss,
More news about: Primally Pure
May 26, 2026, 08:36 ET Eight Munley Law Attorneys Recognized by Super Lawyers
third consecutive year.Also named as 2026 Pennsylvania Super Lawyers are:J. Christopher MunleyRobert W. Munley, IIIJohn M. MulcaheyMelinda C. GhilardiKatie NealonSuper Lawyers, part of Thomson Reuters, is a rating service of
More news about: Munley Law Personal Injury Attorneys
May 26, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.39 Million Tokens, and Total Crypto and Total Cash Holdings of $12.3 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH
More news about: Bitmine Immersion Technologies, Inc.
May 26, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.39 Million Tokens, and Total Crypto and Total Cash Holdings of $12.3 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
May 26, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) anuncia que sus tenencias de ETH alcanzan los 5,39 millones de tokens
con el respaldo de un selecto grupo de inversores institucionales, entre los que se incluyen Cathie Wood de ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital y el inversor particular Thomas «Tom» Lee, para apoyar el objetivo de Bitmine de adquirir el 5% de ETH.
More news about: Bitmine Immersion Technologies, Inc.
May 26, 2026, 08:30 ET Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
with the full autoimmune drug development process and regulatory submission requirements, ensuring efficient project execution and delivery.III. Core Service Capabilities: Multi-Species Autoimmune Models + Standardized Processes + End-to-End Pharmacology Evaluation(1) Rapid Screening
More news about: HKeyBio